CJC-1295 (no DAC)
Short-acting GHRH analogue without the DAC modification, used in growth hormone research.
- 1–2 pcs€120 each
- 3+ pcs€108 each−10%
- 10+ pcs€96 each−20%
- Certificate of analysis for every batch
- Over 99% verified purity
- Ships within 24 hours
- Free shipping over €250
Description and specifications
Description
CJC-1295 (no DAC), also referred to as modified GRF 1-29, is a synthetic GHRH analogue without the DAC modification. In research models, the peptide is studied for its role in pulsatile growth hormone secretion and pituitary-based signalling. Supplied as a lyophilised powder for laboratory use. For research use only (in vitro / laboratory use). Not for consumption, diagnostic or therapeutic use.
Research summary
CJC-1295 (no DAC) is often used as the name for a short-acting GHRH/GRF 1-29 analogue without the albumin-binding DAC extension. Its purpose in research is to study the role of the GHRH receptor in the pituitary gland's release of growth hormone. Direct literature on the "no DAC" variant specifically is limited, so this page clearly marks which data are related GHRH data.
Level of evidence: For the no-DAC variant the documentation is indirect and should be described conservatively. There are human studies on GHRH(1-29) analogues and a clear study on CJC-1295 with DAC, but these are not the same product.
This information is written for a laboratory and research context. The product is not intended for consumption, diagnostics or therapeutic use.
Specifications
| CAS | — |
| Molecular formula | — |
| Purity | ≥ 99 % (HPLC) |
| Size | 10 mg |
Batch information
Batch number, purity and document status are shown here for each published batch.
Need the certificate of analysis?
Contact ArcticAmino to receive a copy of the certificate of analysis (COA) for the product or batch.
Peptide guide
Research Use Only. Not for human consumption. Not medical advice. Always check information against primary sources and internal laboratory procedures.
Read the full guide (3 studies)CJC-1295 (no DAC) / modified GRF 1-29
The GHRH signal acts via receptors in the pituitary gland and can stimulate the release of growth hormone. The DAC modification in CJC-1295 was developed to prolong the duration of action through albumin binding; the no-DAC variant is therefore understood as a shorter GHRH analogue. This is relevant to laboratory research on the GH-IGF-1 axis, but is not a recommendation for use.
What is being researched?
- GH response after GHRH(1-29) analogues in humans
- The difference between short-acting GHRH analogues and albumin-bound variants
- The GH-IGF-1 axis and pituitary signalling
- Regulatory and misuse-related issues around GH-modulating peptides
Selected sources
How your order is handled
How an order moves from request to delivery.
Order
You send the order with the items and your contact details.
Approval
We review and approve the order.
Payment
You pay with your chosen payment method.
Delivery
The items are shipped in discreet packaging.
Why researchers choose ArcticAmino
- Certificate of analysis for every batch
- Over 99% verified purity
- Ships within 24 hours
- Ships within 24 hours
- Discreet packaging
- Customer service by email and Telegram
- Free shipping over €250
- For research purposes only
Often ordered together for lab set-ups.
